QL Biopharm announces new obesity drug results
QL Biopharm, a clinical stage biopharmaceutical company developing biologic drugs for the treatment of metabolic diseases, has shared Phase Ic clinical data for its lead drug candidate ZT002.
The data was presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024, Madrid, Spain. The presentation was titled ‘ZT002, a novel ultra long-acting GLP-1 receptor agonist in adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose Phase Ic study’.
The presentation highlighted recent findings on ZT002 – a novel ultra long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA) in development for obesity with monthly subcutaneous administration.
Study details
The study enrolled 28 overweight/obese patients in Part A in two cohorts. Eligible participants were randomly assigned to receive biweekly (Q2W) subcutaneous injections of ZT002 (dose escalated to 40 or 80mg; n=10+10) or matched placebo (n=4+4) for a 12- or 14- week treatment period, in the 40mg and 80mg dose arms, respectively.
The primary endpoints were safety and tolerability, and secondary endpoints were pharmacokinetics, pharmacodynamics, and immunogenicity. All endpoints were met. Following a six-week off-drug period, for assessment of pharmacokinetics, Part A was followed by an open-label extension (Part B).
In this extension, patients from the ZT002 80mg Q2W cohort voluntarily participated in an additional 12 weeks of treatment with a once-monthly (Q4W) administration of ZT002 120mg (n=8). The primary endpoints were safety and tolerability, and secondary endpoints were pharmacokinetics, pharmacodynamics, and immunogenicity. All endpoints were met.
Key presentation conclusions
ZT002 was considered safe and well tolerated across the investigated dose range, with a favourable tolerability profile aligned with the GLP-1RA class. The tolerability with both Q2W and Q4W dosing improved over time.
The majority of adverse events (AEs) were mild or moderate in severity, no serious AEs were reported in the ZT002 treatment groups.
Gastrointestinal (GI) treatment emergent adverse events were consistent with the GLP-1RA class: Most common treatment-related adverse events were nausea, vomiting, and diarrhoea, occurring primarily during dose escalation and decreasing once target dose was reached.The GI AE profile of monthly dosing in Part B appeared similar to biweekly dosing in Part A.
In Part A, ZT002 demonstrated statistically significantly higher weight reduction compared to placebo with:
- 13% body weight reduction from baseline to 14 weeks with ZT002 80mg Q2W (p<0.001 vs placebo 1.7% body weight reduction)
- 9.6% body weight reduction from baseline to 12 weeks with ZT002 40mg Q2W (p<0.001 vs placebo 0.8% body weight reduction)
In Part B, a 17.1% body weight reduction from baseline was seen at 30 weeks, when further administering ZT002 120mg once-monthly (after a six-week off-drug period).
All doses of ZT002 showed improved cardiometabolic parameters including blood pressure, waist circumference, insulin sensitivity, lipids, and liver enzyme levels.
The results support further clinical investigation of ZT002 dosed monthly as a treatment for obesity.
A Phase II programme evaluating ZT002 for chronic weight management has been initiated in China and regulatory interaction is planned with US FDA to advance the programme outside China.
Dr Zhang Xujia, Founder, Chairman and Chief Executive Officer of QL Biopharm, said: “We are pleased to present data highlighting the potential of ZT002 and its promising clinical profile in obesity care. The additional advantage of monthly dosing simplifies life for patients living with obesity. We look forward to advancing the Phase II programme for ZT002 in overweight and obesity and providing further updates in due course.”
Megan Thomas, Multimedia Editor, DDW
